892 related articles for article (PubMed ID: 29440896)
1. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
2. The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route.
Jiang Y; Liu C; Zhai W; Zhuang N; Han T; Ding Z
Int J Nanomedicine; 2019; 14():9217-9234. PubMed ID: 31819426
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
4. N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption.
Sheng J; Han L; Qin J; Ru G; Li R; Wu L; Cui D; Yang P; He Y; Wang J
ACS Appl Mater Interfaces; 2015 Jul; 7(28):15430-41. PubMed ID: 26111015
[TBL] [Abstract][Full Text] [Related]
5. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects.
Yan X; Xu L; Bi C; Duan D; Chu L; Yu X; Wu Z; Wang A; Sun K
Int J Nanomedicine; 2018; 13():273-281. PubMed ID: 29391788
[TBL] [Abstract][Full Text] [Related]
6. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
7. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the "Nose-to-Brain" Pathways in Intranasal HupA Nanoemulsions and Evaluation of Their in vivo Pharmacokinetics and Brain-Targeting Ability.
Jiang Y; Jiang Y; Ding Z; Yu Q
Int J Nanomedicine; 2022; 17():3443-3456. PubMed ID: 35959279
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of α-asarone to the brain with lactoferrin-modified mPEG-PLA nanoparticles prepared by premix membrane emulsification.
Pan L; Zhou J; Ju F; Zhu H
Drug Deliv Transl Res; 2018 Feb; 8(1):83-96. PubMed ID: 29134552
[TBL] [Abstract][Full Text] [Related]
10. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
11. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery.
Yu Y; Pang Z; Lu W; Yin Q; Gao H; Jiang X
Pharm Res; 2012 Jan; 29(1):83-96. PubMed ID: 21979908
[TBL] [Abstract][Full Text] [Related]
13. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC; Chen YC
Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309
[TBL] [Abstract][Full Text] [Related]
14. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Muntimadugu E; Dhommati R; Jain A; Challa VG; Shaheen M; Khan W
Eur J Pharm Sci; 2016 Sep; 92():224-34. PubMed ID: 27185298
[TBL] [Abstract][Full Text] [Related]
15.
Zhang L; Yang S; Wong LR; Xie H; Ho PC
Mol Pharm; 2020 Nov; 17(11):4256-4269. PubMed ID: 33084343
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
17. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
18. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease.
Tang S; Wang A; Yan X; Chu L; Yang X; Song Y; Sun K; Yu X; Liu R; Wu Z; Xue P
Drug Deliv; 2019 Dec; 26(1):700-707. PubMed ID: 31290705
[TBL] [Abstract][Full Text] [Related]
19. Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine - Development & characterization in physiologically relevant 3D tissue models.
Gadhave DG; Quadros M; Ugale AR; Goyal M; Ayehunie S; Gupta V
Int J Biol Macromol; 2024 May; 267(Pt 2):131491. PubMed ID: 38599435
[TBL] [Abstract][Full Text] [Related]
20. Controlled synthesis of in-situ gold nanoparticles onto chitosan functionalized PLGA nanoparticles for oral insulin delivery.
Asal HA; Shoueir KR; El-Hagrasy MA; Toson EA
Int J Biol Macromol; 2022 Jun; 209(Pt B):2188-2196. PubMed ID: 35504421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
